Showing 13,521 - 13,540 results of 39,062 for search '(( 5 ((step decrease) OR (mean decrease)) ) OR ( 100 ((teer decrease) OR (a decrease)) ))', query time: 1.04s Refine Results
  1. 13521
  2. 13522
  3. 13523
  4. 13524
  5. 13525

    Heat-Resistant Shape Memory Fully Biobased Epoxy Resins with High Storage Modulus and Recycle Performance by Hubiao Yang (579341)

    Published 2024
    “…Combining high heat resistance and green sustainability is a great challenge in developing shape memory epoxy resins. …”
  6. 13526

    Effect of rapamycin (1 ng/ml) and anti-EGFR antibody (5 µg/ml) on reactivity with monoclonal HMB45 in human TSC2<sup>−/−</sup>ASM cells. by Elena Lesma (269724)

    Published 2008
    “…A: Incubation at cell plating time with anti-EGFR for 48 hours decreases markedly the number of cells reacting to HMB45 while the number of negative cells is strongly increased. …”
  7. 13527
  8. 13528
  9. 13529

    qRT-PCR analysis of the relative expression levels of TGF-β1, BMP-4 and Smads in embryonic bladders from E12.5 to neonatal day0. by Syed S. Islam (404861)

    Published 2013
    “…Smad4 showed the highest expression pattern from E12.5 to E16.5 and decreased in E18.5 and neonatal day0 <i>(Mann-Whitney test, p<0.005)</i> and <b>D</b>) Inhibitory Smads. …”
  10. 13530
  11. 13531
  12. 13532
  13. 13533
  14. 13534
  15. 13535

    Baseline characteristics of the study sample<sup>β</sup>μ. by Osama Mohamed Ibrahim (12006954)

    Published 2024
    “…Pharmacists in Active Group A (37.2%) and Active Group B (32.3%) most commonly intervened by recommending the cessation of medication, while the most common intervention in the Control Group was recommending a decrease in dose (29.8%). The mean cost reduction per patient was highest in Active Group A (31.3 ±11.8 $), followed by Active Group B (20.8 ±8.6 $) and the Control Group (19.6 ±9.5 $). …”
  16. 13536

    The flow diagram of the study (CONSORT, 2010). by Osama Mohamed Ibrahim (12006954)

    Published 2024
    “…Pharmacists in Active Group A (37.2%) and Active Group B (32.3%) most commonly intervened by recommending the cessation of medication, while the most common intervention in the Control Group was recommending a decrease in dose (29.8%). The mean cost reduction per patient was highest in Active Group A (31.3 ±11.8 $), followed by Active Group B (20.8 ±8.6 $) and the Control Group (19.6 ±9.5 $). …”
  17. 13537

    Table_1_Incidence and risk factors of severe acute high-altitude illness in healthy adults first entering the northern Tibetan Plateau of over 5,000 m.DOC by Chun Gao (622218)

    Published 2024
    “…</p>Conclusion<p>Living at lower altitudes and having a decreased lymphocyte level were the risk factors of severe AHAI in healthy adults first entering the plateau of over 5,000 m.…”
  18. 13538
  19. 13539

    Systemic 5-FU treatment caused delayed increases in auditory brainstem response (ABR) inter-peak latencies P2-P1 and P3-P1 by Ruolan Han (35102)

    Published 2011
    “…At the later time points day 14 and day 56, both P2-P1 and P3-P1 inter-peak latency values of 5-FU-treated animals show average increases of more than 0.13 ms, whereas the same inter-peak latency values of sham-treated controls show average decreases or an increase of less than 0.04 ms. …”
  20. 13540